Zusammenfassung
Komorbiditäten der idiopathischen Lungenfibrose (IPF) sind sehr häufig und zumeist mit einer verschlechterten Lebensqualität und Prognose der Patienten verbunden. Vor allem pulmonale Hypertonie, chronische obstruktive Lungenerkrankung/Lungenemphysem, Lungenkarzinom und die koronare Herzerkrankung sind prognostisch relevant. Während Mikroaspirationen zwar als möglicher Auslöser und Progressionsfaktor einer IPF diskutiert werden, ist die Refluxerkrankung jedoch mit einer besseren Prognose assoziiert. Die Ursachen hierfür sind noch unklar, möglicherweise handelt es sich um einen „lead time bias“ oder einen Therapieeffekt des Refluxes; allerdings spricht die aktuelle Datenlage gegen einen solchen Zusammenhang für antazide Medikamente. Das Risiko ein Lungenkarzinom zu entwickeln, ist bei IPF signifikant höher im Vergleich zur Normalbevölkerung und die zweithäufigste respiratorische Todesursache bei der IPF. Eine Therapie des nicht-kleinzelligen Bronchialkarzinoms (NSCLC) ist jedoch nur im frühen Stadium der IPF mit einem verbesserten Outcome assoziiert, in anderen Fällen allerdings mit einem sehr hohen periinterventionellen Risiko. Bisherige Daten suggerieren, dass ein Screening auf Komorbiditäten und deren konsequente Therapie zu einer verbesserten Lebensqualität und Prognose der chronisch erkrankten IPF-Patienten führen könnten.
Abstract
Comorbidities of idiopathic pulmonary fibrosis (IPF) are very frequent and mostly associated with a reduced quality of life and poorer prognosis for the patient. In particular, pulmonary hypertension, chronic obstructive pulmonary disease/lung emphysema, lung cancer and coronary heart disease are prognostically relevant. While microaspiration might be a possible trigger and a progression factor in IPF, gastroesophageal reflux disease (GERD) is associated with a better prognosis. The reasons for this are still unclear but could possibly be explained by a lead time bias or a therapeutic effect of GERD treatment; however, such an association with antacid medication is not supported by the currently available data. The risk of developing lung cancer is significantly higher in IPF than in the general population and is the second most common respiratory cause of death in IPF; however, treatment of non-small cell lung cancer (NSCLC) is only associated with a better outcome in patients with an early stage of IPF, in other cases patients have a higher peri-interventional risk. Current data suggest that screening for comorbidities followed by consistent treatment could lead to an improvement of the quality of life and prognosis in patients with chronic IPF.
Literatur
Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK et al (2011) An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183(6):788–824
Ley B, Collard HR, King TE Jr. (2011) Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 183(4):431–440
Kreuter M, Swigris J, Pittrow D, Geier S, Klotsche J, Prasse A et al (2017) Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registry. Respir Res 18(1):139
Kreuter M, Ehlers-Tenenbaum S, Palmowski K, Bruhwyler J, Oltmanns U, Muley T et al (2016) Impact of comorbidities on mortality in patients with idiopathic pulmonary fibrosis. PLoS ONE 11(3):e151425
Kreuter M, Swigris J, Pittrow D, Geier S, Klotsche J, Prasse A et al (2019) The clinical course of idiopathic pulmonary fibrosis and its association to quality of life over time: longitudinal data from the INSIGHTS-IPF registry. Respir Res 20(1):59
Raghu G, Amatto VC, Behr J, Stowasser S (2015) Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review. Eur Respir J 46(4):1113–1130
Schwarzkopf L, Witt S, Waelscher J, Polke M, Kreuter M (2018) Associations between comorbidities, their treatment and survival in patients with interstitial lung diseases—a claims data analysis. Respir Res 19(1):73
Lee JS, Song JW, Wolters PJ, Elicker BM, King TE Jr., Kim DS et al (2012) Bronchoalveolar lavage pepsin in acute exacerbation of idiopathic pulmonary fibrosis. Eur Respir J 39(2):352–358
Kreuter M, Kirsten D, Bahmer T, Penzel R, Claussen M, Ehlers-Tenenbaum S et al (2016) Screening for helicobacter pylori in idiopathic pulmonary fibrosis lung biopsies. Respiration 91(1):3–8
Lee JS, Ryu JH, Elicker BM, Lydell CP, Jones KD, Wolters PJ et al (2011) Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 184(12):1390–1394
Lee JS, Collard HR, Anstrom KJ, Martinez FJ, Noth I, Roberts RS et al (2013) Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. Lancet Respir Med 1(5):369–376
Raghu G, Rochwerg B, Zhang Y, Garcia CA, Azuma A, Behr J et al (2015) An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med 192(2):e3–19
Kreuter M, Wuyts W, Renzoni E, Koschel D, Maher TM, Kolb M et al (2016) Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis. Lancet Respir Med 4(5):381–389
Kreuter M, Spagnolo P, Wuyts W, Renzoni E, Koschel D, Bonella F et al (2017) Antacid therapy and disease progression in patients with idiopathic pulmonary fibrosis who received pirfenidone. Respiration 93(6):415–423
Costabel U, Behr J, Crestani B, Stansen W, Schlenker-Herceg R, Stowasser S et al (2018) Anti-acid therapy in idiopathic pulmonary fibrosis: insights from the INPULSIS(R) trials. Respir Res 19(1):167
Behr J, Gunther A, Bonella F, Geissler K, Koschel D, Kreuter M et al (2017) German guideline for idiopathic pulmonary fibrosis—update on pharmacological therapies 2017. Pneumologie 71(7):460–474
Raghu G, Pellegrini CA, Yow E, Flaherty KR, Meyer K, Noth I et al (2018) Laparoscopic anti-reflux surgery for the treatment of idiopathic pulmonary fibrosis (WRAP-IPF): a multicentre, randomised, controlled phase 2 trial. Lancet Respir Med 6(9):707–714
Le Jeune I, Gribbin J, West J, Smith C, Cullinan P, Hubbard R (2007) The incidence of cancer in patients with idiopathic pulmonary fibrosis and sarcoidosis in the UK. Respir Med 101(12):2534–2540
Ozawa Y, Suda T, Naito T, Enomoto N, Hashimoto D, Fujisawa T et al (2009) Cumulative incidence of and predictive factors for lung cancer in IPF. Respirology 14(5):723–728
Natsuizaka M, Chiba H, Kuronuma K, Otsuka M, Kudo K, Mori M et al (2014) Epidemiologic survey of Japanese patients with idiopathic pulmonary fibrosis and investigation of ethnic differences. Am J Respir Crit Care Med 190(7):773–779
Baumgartner KB, Samet JM, Stidley CA, Colby TV, Waldron JA (1997) Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 155(1):242–248
Vancheri C (2012) Idiopathic pulmonary fibrosis: an altered fibroblast proliferation linked to cancer biology. Proc Am Thorac Soc 9(3:153–157
Poletti V, Ravaglia C, Buccioli M, Tantalocco P, Piciucchi S, Dubini A et al (2013) Idiopathic pulmonary fibrosis: diagnosis and prognostic evaluation. Respiration 86(1):5–12
Yano M, Sasaki H, Moriyama S, Hikosaka Y, Yokota K, Kobayashi S et al (2012) Post-operative acute exacerbation of pulmonary fibrosis in lung cancer patients undergoing lung resection. Interact Cardiovasc Thorac Surg 14(2):146–150
Han S, Lee YJ, Park JS, Cho YJ, Yoon HI, Lee JH et al (2019) Prognosis of non-small-cell lung cancer in patients with idiopathic pulmonary fibrosis. Sci Rep 9(1):12561
Kreuter M, Ehlers-Tenenbaum S, Schaaf M, Oltmanns U, Palmowski K, Hoffmann H et al (2015) Treatment and outcome of lung cancer in idiopathic interstitial pneumonias. Sarcoidosis, vasculitis, and diffuse lung diseases. Off J WASOG 31(4):266–274
Enomoto T, Usuki J, Azuma A, Nakagawa T, Kudoh S (2003) Diabetes mellitus may increase risk for idiopathic pulmonary fibrosis. Chest 123(6):2007–2011
Kim YJ, Park JW, Kyung SY, Lee SP, Chung MP, Kim YH et al (2012) Clinical characteristics of idiopathic pulmonary fibrosis patients with diabetes mellitus: the national survey in Korea from 2003 to 2007. J Korean Med Sci 27(7):756–760
Hunt WR, Zughaier SM, Guentert DE, Shenep MA, Koval M, McCarty NA et al (2014) Hyperglycemia impedes lung bacterial clearance in a murine model of cystic fibrosis-related diabetes. Am J Physiol Lung Cell Mol Physiol 306(1):L43–9
Kyung SY, Byun KH, Yoon JY, Kim YJ, Lee SP, Park JW et al (2014) Advanced glycation end-products and receptor for advanced glycation end-products expression in patients with idiopathic pulmonary fibrosis and NSIP. Int J Clin Exp Pathol 7(1):221–228
Kheirollahi V, Wasnick RM, Biasin V, Vazquez-Armendariz AI, Chu X, Moiseenko A et al (2019) Metformin induces lipogenic differentiation in myofibroblasts to reverse lung fibrosis. Nat Commun 10(1):2987
Spagnolo P, Kreuter M, Maher TM, Wuyts W, Bonella F, Corte TJ et al (2018) Metformin Does Not Affect Clinically Relevant Outcomes in Patients with Idiopathic Pulmonary Fibrosis. Respiration 96(4):314–322
Mermigkis C, Bouloukaki I, Schiza SE (2017) Sleep as a new target for improving outcomes in idiopathic pulmonary fibrosis. Chest 152(6):1327–1338
Mermigkis C, Bouloukaki I, Antoniou K, Papadogiannis G, Giannarakis I, Varouchakis G et al (2015) Obstructive sleep apnea should be treated in patients with idiopathic pulmonary fibrosis. Sleep Breath 19(1):385–391
Collard HR, Ward AJ, Lanes S, Hayflinger CD, Rosenberg DM, Hunsche E (2012) Burden of illness in idiopathic pulmonary fibrosis. J Med Econ 15(5):829–835
Nathan SD, Basavaraj A, Reichner C, Shlobin OA, Ahmad S, Kiernan J et al (2010) Prevalence and impact of coronary artery disease in idiopathic pulmonary fibrosis. Respir Med 104(7):1035–1041
Bansilal S, Castellano JM, Fuster V (2015) Global burden of CVD: focus on secondary prevention of cardiovascular disease. Int J Cardiol 201(Suppl 1):S1–7
Cholesterol Treatment Trialists C, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C et al (2010) Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376(9753):1670–1681
Xu JF, Washko GR, Nakahira K, Hatabu H, Patel AS, Fernandez IE et al (2012) Statins and pulmonary fibrosis: the potential role of NLRP3 inflammasome activation. Am J Respir Crit Care Med 185(5:547–556
Kreuter M, Bonella F, Maher TM, Costabel U, Spagnolo P, Weycker D et al (2017) Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis. Thorax 72(2):148–153
Kreuter M, Lederer DJ, Molina-Molina M, Noth I, Valenzuela C, Frankenstein L et al (2019) Association of angiotensin modulators with the course of idiopathic pulmonary fibrosis. Chest 156(4):706–714
Kotani I, Sato A, Hayakawa H, Urano T, Takada Y, Takada A (1995) Increased procoagulant and antifibrinolytic activities in the lungs with idiopathic pulmonary fibrosis. Thromb Res 77(6):493–504
Kubo H, Nakayama K, Yanai M, Suzuki T, Yamaya M, Watanabe M et al (2005) Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest 128(3):1475–1482
Noth I, Anstrom KJ, Calvert SB, de Andrade J, Flaherty KR, Glazer C et al (2012) A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 186(1):88–95
Kreuter M, Wijsenbeek MS, Vasakova M, Spagnolo P, Kolb M, Costabel U et al (2016) Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis: methodological concerns. Eur Respir J 48(5):1524–1526
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
M. Polke und M. Kreuter geben an, dass kein Interessenkonflikt besteht.
Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.
Additional information
Redaktion
U. Costabel, Essen
J. Behr, München
Rights and permissions
About this article
Cite this article
Polke, M., Kreuter, M. Bedeutung von Komorbiditäten bei der idiopathische Lungenfibrose. Pneumologe 17, 169–176 (2020). https://doi.org/10.1007/s10405-019-00294-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10405-019-00294-5
Schlüsselwörter
- Lungenfibrose
- Komorbiditäten
- Lebensqualität
- Gastroösophageale Refluxerkrankung
- Nicht-kleinzelliges Bronchialkarzinom